Quarterly ResultMay 13, 2026, 04:14 PM
Aytu BioPharma Q3 Net Loss $5.6M; Revenue Falls to $12.4M
AI Summary
Aytu BioPharma reported a net loss of $5.6 million for the three months ended March 31, 2026, a significant decline from a net income of $4.0 million in the prior year, with net revenue decreasing to $12.4 million. The company launched EXXUA in the second quarter of fiscal 2026 as a key commercial product and completed the divestment of its Consumer Health business in fiscal 2025. Stockholders' equity increased to $35.1 million, primarily due to the reclassification of $26.4 million in derivative warrant liabilities to equity.
Key Highlights
- Net loss for Q3 2026 was $5.6 million, compared to net income of $4.0 million in Q3 2025.
- Net revenue for Q3 2026 decreased 32.8% to $12.4 million from $18.5 million in Q3 2025.
- Basic net loss per share was $0.53 for Q3 2026, down from $0.65 basic net income per share in Q3 2025.
- EXXUA generated $2.4 million in net revenue for Q3 2026, its first full quarter of sales.
- ADHD Portfolio net revenue was $9.1 million in Q3 2026, down from $15.4 million in Q3 2025.
- Stockholders' equity increased to $35.1 million, partly due to $26.4 million reclassification of derivative warrant liabilities.
- Cash and cash equivalents were $26.7 million as of March 31, 2026, down from $31.0 million at June 30, 2025.
- Net cash used in operating activities improved to $1.1 million for the nine months ended March 31, 2026.
Price Impact
More from AYTU